Commentary

Video

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

Steven H. Lin, MD, PhD, discusses the safety of NKTR-255 in enhancing immune recovery post-chemoradiation in locally advanced NSCLC.

There was adequate restoration of lymphocyte counts after chemoradiation therapy with NKTR-255. Now, after the first 10 patients, the study continues to enroll [with a goal of] an additional 20 patients for a total of 30 patients on the study. We're going to look at the continued evaluation of safety, lymphocyte recovery, [and] preliminary efficacy in this group of patients.”

Steven H. Lin, MD, PhD, physician-scientist, radiation oncologist, professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Center, discusses findings from the phase 2 RESCUE study (NCT05632809) evaluating NKTR-255, a novel polymer-conjugated recombinant human interleukin 15 agonist, in patients with locally advanced non-small cell lung cancer (NSCLC) with radiation-induced lymphopenia following concurrent chemoradiation. Data were presented by Lin and colleagues at the 2024 SITC Annual Meeting.

The study evaluated NKTR-255 in combination with durvalumab (Imfinzi), and the combination was started following the completion of chemoradiation. The agents were administered on day 0 after chemoradiation and administered once every 4 weeks for up to 1 year. The primary objectives focused on safety and lymphocyte recovery, Lin begins. Preliminary efficacy was also assessed as a secondary end point.

Findings showed that in the first cohort of 10 patients, 9 experienced a complete recovery of lymphocyte counts by week 8, Lin explains. He notes that data from historical controls show that lymphocyte recovery would be expected in only a small number of patients at this time point, indicating that NKTR-255 plays a role in lymphocyte recovery.

In terms of safety, Lin noted that NKTR-255 was well tolerated when combined with durvalumab. Low-grade adverse effects including mild fever, chills, and fatigue were reported, and no high-grade AEs were observed, Lin notes. Grade 3 pneumonitis was reported in 1 patient, which was consistent with expected rates in this population, Lin adds.

As patients continue to enroll on the study, investigators will continue to evaluate the safety of NKTR-255 and the lymphocyte recovery achieved by patients, along with additional analysis to examine efficacy, Lin concludes.

Related Videos
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University